Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
2.450
+0.020 (0.82%)
At close: Aug 13, 2025, 4:00 PM
2.470
+0.020 (0.82%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Cardiff Oncology Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$16,515
Profits / Employee
-$1,546,758
Market Cap
162.99M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRDF News
- 14 days ago - Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data? - Benzinga
- 14 days ago - Cardiff Oncology: Data Update Resolves Some Signals - Seeking Alpha
- 15 days ago - Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) - GlobeNewsWire
- 6 weeks ago - Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
- 2 months ago - Cardiff Oncology Names Roger Sidhu as Medical Chief - Market Watch
- 2 months ago - Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC - GlobeNewsWire
- 2 months ago - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - GlobeNewsWire
- 3 months ago - Cardiff Oncology: Buying The First-Line Onvansertib Strategy - Seeking Alpha